Non-mRNA jab targeting common mutations in pancreatic and bowel cancers could lower risk of relapse

Non-mRNA jab targeting common mutations in pancreatic and bowel cancers could lower risk of relapse

Researchers found patients with pancreatic cancer and bowel cancer survived more than two years after receiving the vaccine

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small UCLA clinical trial suggests.